Last reviewed · How we verify
Guangzhou JOYO Pharma Co., Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
4 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Cross-over to JYP0322 | Cross-over to JYP0322 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes | |
| JYP0322 tablets | JYP0322 tablets | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes |
Therapeutic area mix
- Diabetes · 2
- Oncology · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 2 shared drug classes
- Teva Branded Pharmaceutical Products R&D, Inc. · 2 shared drug classes
- GlaxoSmithKline · 2 shared drug classes
- AJU Pharm Co., Ltd. · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Abbott · 1 shared drug class
- Aciex Therapeutics, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Guangzhou JOYO Pharma Co., Ltd:
- Guangzhou JOYO Pharma Co., Ltd pipeline updates — RSS
- Guangzhou JOYO Pharma Co., Ltd pipeline updates — Atom
- Guangzhou JOYO Pharma Co., Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Guangzhou JOYO Pharma Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/guangzhou-joyo-pharma-co-ltd. Accessed 2026-05-16.